Abstract:Glioblastoma (GBM) is the most common type of malignant tumor of the central nervous system. The prognosis of patients with GBM is very poor, with a survival time of ~15 months. GBM is highly heterogeneous and highly aggressive. Surgical removal of intracranial tumors does provide a good advantage for patients as there is a high rate of recurrence. The understanding of this type of cancer needs to be strengthened, and the aim of the present study was to identify gene signatures present in GBM and uncover their potential mechanisms. The gene expression profiles of GSE15824 and GSE51062 were downloaded from the Gene Expression Omnibus database. Normalization of the data from primary GBM samples and normal samples in the two databases was conducted using R software. Then, joint analysis of the data was performed. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed, and the protein‑protein interaction (PPI) network of the differentially expressed genes (DEGs) was constructed using Cytoscape software. Identification of prognostic biomarkers was conducted using UALCAN. In total, 9,341 DEGs were identified in the GBM samples, including 9,175 upregulated genes and 166 downregulated genes. The top 1,000 upregulated DEGs and all of the downregulated DEGs were selected for GO, KEGG and prognostic biomarker analyses. The GO results showed that the upregulated DEGs were significantly enriched in biological processes (BP), including immune response, cell division and cell proliferation, and the downregulated DEGs were also significantly enriched in BP, including cell growth, intracellular signal transduction and signal transduction by protein phosphorylation. KEGG pathway analysis showed that the upregulated DEGs were enriched in circadian entrainment, cytokine‑cytokine receptor interaction and maturity onset diabetes of the young, while the downregulated DEGs were enriched in the TGF‑β signaling pathway, MAPK signaling pathway and pathways in cancer. All of the downregulated genes and the top 1,000 upregulated genes were selected to establish the PPI network, and the sub‑networks revealed that these genes were involved in significant pathways, including olfactory transduction, neuroactive ligand‑receptor interaction and viral carcinogenesis. In total, seven genes were identified as good prognostic biomarkers. In conclusion, the identified DEGs and hub genes contribute to the understanding of the molecular mechanisms underlying the development of GBM and they may be used as diagnostic and prognostic biomarkers and molecular targets for the treatment of patients with GBM in the future.

Differential gene expression analysis in glioblastoma cells and normal human brain cells based on GEO database

Screening of differentially expressed genes associated with human glioblastoma and functional analysis using a DNA microarray.

Identification of Novel Human Glioblastoma-Specific Transcripts by Serial Analysis of Gene Expression Data Mining

Identification of Differential Splicing Genes in Gliomas Using Exon Expression Profiling.

Identification of Differentially Expressed Key Genes Between Glioblastoma and Low-Grade Glioma by Bioinformatics Analysis.

The Comparison Genomics Analysis with Glioblastoma Multiforme (GBM) Cells under 3D and 2D Cell Culture Conditions

Identification of Core Genes and Screening of Potential Targets in Glioblastoma Multiforme by Integrated Bioinformatic Analysis

Bioinformatics analyses of significant genes, related pathways and candidate prognostic biomarkers in glioblastoma

[Cluster Analysis and Identify Significance of Novel Genes Related to Glioma in Molecule Classification].

Identification of Key Candidate Genes and Pathways in Glioblastoma by Integrated Bioinformatical Analysis

Comprehensive Analysis of the Brain-Expressed X-Link Protein Family in Glioblastoma Multiforme

Identification of novel prognostic targets in glioblastoma using bioinformatics analysis

Analysis of Differentially Expressed Genes Based on Microarray Data of Glioma.

Bioinformatics Analysis of High-Throughput Data to Validate Potential Novel Biomarkers and Small Molecule Drugs for Glioblastoma Multiforme

Bioinformatic Analysis of Gene Expression and Methylation Regulation in Glioblastoma

Identification of biomarkers and ceRNA network in glioblastoma through bioinformatic analysis and evaluation of potential prognostic values

Identification of potential biomarkers and candidate small molecule drugs in glioblastoma

Integrative analysis of DNA methylation and gene expression profiles to identify biomarkers of glioblastoma

Analysis of gene expression profiles associated with glioma progression.

Genome-wide Expression Profiling of Glioblastoma Using a Large Combined Cohort.

Identification Of Ugp2 As A Progression Marker That Promotes Cell Growth And Motility In Human Glioma